(Hedgeweek) Hedge fund Farallon Capital Management is planning to launch a proxy fight at biotech Exelixis Inc with the nomination of three directors to the board of the cancer drug maker, according to a report by The Wall Street Journal (WSJ).
(Hedgeweek) Hedge fund Farallon Capital Management is planning to launch a proxy fight at biotech Exelixis Inc with the nomination of three directors to the board of the cancer drug maker, according to a report by The Wall Street Journal (WSJ).